It is difficult to predict relapse in patients with stage II colorectral cancer (CRC). In recent years, circulating cell-free DNA (cfDNA) from peripheral blood represents a promising biomarker for detection, monitoring and survival prediction of metastatic colorectal cancer (CRC). However, its prognostic significance in patients with stage II CRC remains uncertain.
In this study, the blood samples were drawn from mesenteric vein (MV) and peripherial vein (PV). MV and PV cfDNA level was quantified by real-time quantitative PCR of ALU repeats. The cfDNA from MV and PV was quantified and the correlation among the cfDNA concentration, clinicopathological features and multivariate survival was analyzed in CRC patients.
Our results showed the MV cfDNA concentrations were lower in early stage than late stage CRC. We also found that MV cfDNA level was positively correlated with tumor size. Stage II CRC patients with higher cfDNA concentrations have better prognosis than those with lower cfDNA concentrations.
These results indicated that MV cfDNA concentration has prognostic value in stage II CRC patients and may act as an additional biomarker in stage II CRC patients for receiving chemotherapy criteria.
Clinical trial identification
Legal entity responsible for the study
Has not received any funding.
All authors have declared no conflicts of interest.